Heart failure occurs 550,000 times a year in the U.S., with an annual mortality of 266,000. Roughly 8% of people aged 65 or over have heart failure. There are presently 5,000,000 patients with heart failure in the U.S. and it is projected that by the year 2037 the number will double to 10,000,000. The annual cost of heart failure is $38 billion dollars, and 60% of the costs are related to hospitalization.
One of the treatments for people with moderate to severe heart failure is a device therapy known as cardiac resynchronization therapy (CRT). CRT can also be combined with implantable cardioverter-defibrillator (ICD) therapy to eliminate life-threatening tachyarrhythmias.
The ICD is an electronic device consisting of a generator and a lead system. The purposes of the device are to monitor heart rhythm and treat detected abnormal heart rhythms using variable modalities.
Improvements in generator technology have increased the options for treating tachyarrhythmias. These options now include electrical therapy (pacing), which is used to treat bradyarrhythmias. Thus, sustained ventricular tachycardia can be treated with competitive (overdrive) pacing or synchronized cardioversion, ventricular fibrillation can be treated with defibrillation, and bradycardia can be treated with pacing.
The lead system connects the generator of the ICD to the heart. This system allows heart rate to be detected and electrical therapies to be delivered. Lead technology has progressed rapidly in the past 10 years. Implantation no longer requires open-heart surgery and placement of electrical patches on the ventricle. Most ICDs now require only a single lead that can be placed transvenously. Since the generator forms one electrical pole of the cardioversion-defibrillation circuit, a second lead is not needed. However, devices that employ defibrillation patches on the ventricle are still in use, and these leads are usually retained when a generator is upgraded.
With permanent systems, endocardial leads are inserted into the venous system, usually via the subclavian, axillary, or cephalic vein, and advanced to the right ventricle and/or atrium. Newer pacing systems may have 2 atrial leads, one in the right atrial appendage and the other either in the coronary sinus or at the os of the coronary sinus, with the ventricular lead in the right ventricle, either at the apex or at the outflow tract. This dual site or biatrial pacing system is used to prevent or minimize bouts of atrial fibrillation. Another new pacing system is biventricular pacing with 2 ventricular leads, one in the right ventricle and the other in a venous branch of the coronary sinus.
Current ICDs store information about the arrhythmias. This information can be retrieved by interrogation of the ICD. This can be achieved by communicating via inductive coupling with an antenna placed over the device and attached to a programmer. The programmer is specific to the device of each manufacturer. Interrogation allows the physician to determine which electrical therapies have been given. Lead integrity and battery status are also checked. The device can then be adjusted to optimize detection and therapy parameters. Most ICDs also record the patient's electrocardiographic tracing at the time of arrhythmia detection. This information can be analyzed at follow-up visits to determine the nature of the arrhythmia and the efficacy of the electrical therapy that was given.
The variability of coronary venous anatomy sometimes makes the implantation of cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) devices difficult, even impossible to achieve. In addition to the placement of the electronic devices under the skin, single or multiple lead wires must be advanced venously under fluoroscopic guidance into one or more chambers of the heart muscle. Insertion is further hampered by the inability to inject contrast agents into veins and the 2D nature of fluoroscopic imaging.
In approximately 10% of cases, the procedure is aborted, typically due to the size, shape or location of the patient's vein. While the 10% may seem statistically acceptable, the percentage is problematic due to the high number of cases presented each year and the dire consequences of poor results. The ICD/CRT market is currently the largest cardiac device market with annual sales of approximately $10 billion worldwide.
In the normal heart, the heart's lower chambers (ventricles) pump at the same time and in sync with the heart's upper chambers (atria). When a patient has heart failure, often times the right and left ventricles do not pump together (dysynchrony). When the heart's contractions become out of sync, the walls of left ventricle (LV) do not contract at the same time. The heart has less time to fill with blood and is not able to pump enough blood out to the body. This eventually leads to an increase in heart failure symptoms.
Biventricular pacing keeps the right and left ventricles pumping synchronously together by sending small electrical impulses through the leads. When the atrium contracts, both ventricles are paced to contract at the same time, causing the walls of the left ventricle (the septal and free walls) to contract “in synch.” This allows the left ventricle (LV) and the right ventricle (RV) to pump together and also both walls of the left ventricle. Besides coordinating contractions, biventricular pacing reduces the amount of blood flow that leaks through the mitral valve and decreases the motion of the septal wall that separates the chambers of the heart. The end result is improved cardiac function.
Two leads are placed into a vein, and then guided to the right atrium and right ventricle of the patient's heart. The lead tips are attached to the heart muscle. The other ends of the leads are attached to the pulse generator, which is placed under the skin in the upper chest. The third, left ventricular lead is guided through the vein to a small vein on the back of the heart called the coronary sinus to pace the left ventricle.
It is interesting to note that the leads, once placed, are in an ideal position for measuring heart wall motions, if an appropriate mechanism could be ascertained. Quantitative measurement of left ventricular wall motion can improve clinical diagnosis by providing a more objective approach than qualitative analysis, which is subject to large inter-observer variability. It is known that wall motion analysis can successfully detect ischemia and provides an objective and quantitative approach for detecting and assessing the severity of disease. This information, besides being clinically important by itself, may further improve the control of heart rhythm management.
Many previous attempts at measuring heart wall motion utilize accelerometers, whose outputs are then integrated twice to determine displacement. Examples of this can be found in U.S. Pat. Nos. 5,480,412; 5,496,361; 5,628,777; 5,991,661; 6,002,963; 6,009,349 and 6,923,772. The drawbacks to this approach include (1) the fact that no absolute position reference is obtained, and (2) the inaccuracies that build up with a double integration of the data.
The present invention relates to Lead Tracking of Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Devices. The present invention improves upon the process of implantation of ICD-CRT devices, placing their leads, and improving the information fed back to the device and/or clinician. This is accomplished by tracking the placement of the leads during implantation and monitoring the leads once implanted. Benefits include reducing the risk and complication rate, simplifying the procedure, and enabling the extraction of vital data not previously available.
The present invention includes the following interrelated objects, aspects and features:
1. Quantifiable assessment of cardiac performance over time.
2. Volumetric measurement within the beating heart.
3. Real-time 3D visualization of lead tips as they are advanced into the heart.
4. Ability to instantly visualize changes in lead placement caused by physical rotation of the proximal end of the insertion wire.
5. Simplification of lead placement for bi-ventricular tracing.
As explained hereinafter, one or more tracking means, such as static magnetic, pulsed DC magnetic, AC magnetic, and magnetic resonance can accomplish 3D localization of lead wires. A wireless tracking means is preferred to eliminate fragile wiring and increase reliability. 5 degrees-of freedom (5DOF) tracking is the preferred method for all position and orientation methods since this requires the simplest sensing means and design. 5DOF tracking requires the minimum number of devices, one per lead/device, and provides 3 Cartesian coordinates (x,y,z) and two orientation parameters.
Accordingly, it is a first object of the present invention to provide lead tracking of implantable cardioverter-defibrillator and cardiac resynchronization therapy devices.
It is a further object of the present invention to provide such a method in which the process of installation of implanted devices on the heart is monitored in 5 degrees of freedom.
It is a still further object of the present invention to provide such a method in which the process of installation of implanted devices on the heart is monitored in 6 degrees of freedom.
It is a still further object of the present invention to provide such a method in which tracking is accomplished through wired connection between a sensor and monitoring device.
It is a yet further object of the present invention to provide such tracking using wireless technology.
It is a still further object of the present invention to facilitate monitoring of heart wall motion via tracking of leads.
These and other objects, aspects and features of the present invention will be better understood from the following detailed description of the preferred embodiments when read in conjunction with the appended drawing figures.
All embodiments disclosed herein allow the leads to be tracked, eliminating, or at least minimizing, the use of fluoroscopy. This additional 3-dimensional tracking data also allows the surgeon to better visualize lead insertion and placement, improving the outcome of the procedure. This is accomplished by any of the techniques known in the prior art, in which 3D tracking data is fused with pre-acquired, or real time imaging data from 2D or 3D sources such as MRI, CAT and PET scans.
One preferred embodiment uses a 5 degrees-of-freedom (5DOF) sensor, typically a coil of wire or a single semiconductor device. Such sensors are capable of determining position in 3 dimensions (e.g., x,y,z Cartesian coordinates) and two device orientation parameters such as two of pitch, roll and yaw. A 5DOF tracking system typically uses N transmitters (field generators) and M sensors, with N≧5 and M=1. MN must be ≧5 and is typically 9 for best tracking results. The N measurements are typically used in a least squares algorithm to determine position and orientation. Examples of these types of systems can be found in U.S. Pat. Nos. 4,622,644; 4,710,708; 5,592,939; 6,052,547; 6,226,547; 6,385,482; 6,427,079; 6,484,118; 6,690,963; 6,701,179 and 6,836,745, incorporated by reference. Of course, 6DOF tracking is also feasible using techniques known in the art. Wireless variations are also available. All of the methods provide accurate position and/or orientation measurement capability.
Safely and accurately placing the leads during a procedure requires using an external tracking component (versus an embedded one) along with a means and method of tracking the implantable leads. The general configuration for tracking lead placement is schematically shown in
U.S. Pat. No. 6,836,745 generally discusses the algorithmic method of position and orientation solution for these types of trackers. Bladen, in U.S. Pat. No. 6,757,557 discloses both 5DOF and 6DOF solutions to this type of tracker. Differences in antennae geometry sometimes yield different methods of solution. Examples of this are disclosed in U.S. Pat. Nos. 5,592,939; 6,427,079 and 6,701,179, among others. When antennae 11-19 are planar, computational algorithms such as those in U.S. Pat. Nos. 5,752,513; 6,052,610; 6,226,547 and 6,690,963 are possible. Some algorithms work for many different transmitter and sensor configurations and are disclosed in U.S. Pat. Nos. 4,622,644; 4,710,708; 6,073,043; and 6,427,079, among others.
Tracking a coil based sensor location based on the fields generated by an MRI is disclosed in U.S. Pat. Nos. 5,307,808; 5,353,795; 5,947,900; 6,289,233; and 6,687,530, also incorporated by reference. This system uses the pulsed gradient fields developed by the MRI as the “transmitters.” The sensed sensor signal yields a signal that, after processing, is the position of the sensor coil.
In another preferred embodiment, with reference to
In
In an alternative embodiment depicted in the region B in
Further details on the above “retransmission” type system are detailed in
Signals generated across the sensors are amplified at amplifier 161-163, which may have adjustable gain. This gain could be adjusted by circuitry associated with the amplifiers, the signal processor 164 or the central processor 140, depending on the sensor and the tracker architecture. In another configuration, sensor 150B could be a material that affects the generated fields from antennae 111-119 in a manner similar to a resonant circuit. Such a material might be mu-metal, or other high permeability material. Signal processor 140 can perform many other functions and can contain both analog and digital components. Multiplexing, filtering, synchronous demodulation, integration, FFT, correlation and A/D conversion, among other functions, are carried out in this section. The type of transmitter excitation and the sensor means determines what functions are performed. These functions may or may not be under central processor 140 control. The output of signal processor 164, typically a digital signal representing the sensed field, is further processed in an algorithm to determine the position and orientation of the sensor 150. The position and orientation is communicated to the user 191 via an appropriate interface under central processor 140 control. As is also known in the art, antennae 111-119 could be physically split into two separate arrays, 111a-119a for field generation, and 111b-119b for sensing. The operations description would not change. While this introduces additional hardware, it may be advantageous to do so for particular medical procedures where placement, size, etc. add additional design constraints. Algorithms for this type of tracker are the same as for the ones described for
In another embodiment (see
Further details of the above can be found in
As noted previously, more or fewer sensing devices may be used. During operation, the antennae arrays 210 are time multiplexed between amplifiers 261-263. In further configurations, there can be one amplifier per sensor device (211-219), or single amplifiers (261-263) may be multiplexed in time, as is known in the art. Magnet 270A generates a magnetic field. Antennae 211-219 sense this excitation. Signals generated across the sensors are amplified at amplifier 261-263, which may have adjustable gain. This gain can be adjusted by circuitry associated with the amplifiers, the signal processor 264 or the central processor 240, depending on the sensor and the tracker architecture. Signal processor 264 can perform many other functions and can contain both analog and digital components. Multiplexing, filtering, synchronous demodulation, integration, FFT, correlation and A/D conversion, among other functions, are carried out in this section. The type of transmitter excitation and the sensor means determines what functions are performed. These functions may or may not be under central processor 240 control. The output of signal processor 264, typically a digital signal representing the sensed field, is further processed in an algorithm to determine the position and orientation of the sensor 270A or 270B. The position and orientation is communicated to the user 291 via an appropriate interface under central processor 240 control. Examples and algorithms for this type of tracker can be found in U.S. Pat. Nos. 4,622,644 and 6,052,610.
If the sensing devices of
The magnetic field generated by an external transmitter, such as 10 (
Once leads are implanted, the important process becomes monitoring of the heart wall motion via the tracking of the leads. This can be performed using any of the embodiments above within a clinical or home environment. In embodiments disclosed in
A simple method of measuring heart wall motion, based on an implantable magnet and Hall Effect sensors, is disclosed in U.S. Pat. No. 5,161,540, and incorporated herein. This method only provides a range measurement between the Hall elements and the magnet. The preferred approach is to use more advanced, active magnetic tracking technology. Many variations of this technology are available.
It is also advantageous to provide tracking of the leads, and hence the heart wall motion, in real time. This information can then be used with the ICD-CRT unit to further enhance and adapt the therapy applied by this device. In embodiments disclosed in
In another alternative embodiment, with reference back to
These devices 70, 150A, 150B, 270A, 270B and 271 are associated with the lead placement mechanism and can either be at the end of the sheath or at the end of the lead (see
In still another embodiment, the wireless sensor attached to the lead is any material (including a coil of wire) that could cause a highly sensitive, null-balanced detector to become unbalanced (like a metal detector). The amount of unbalance can be correlated to the position and/or orientation of the sensor. Examples of such systems are disclosed in U.S. Pat. Nos. 6,418,335 and 6,541,966, all incorporated herein by reference.
In another embodiment, a sensor on a lead measures magnetic fields from a field generator and a corresponding signal is then transmitted using power from an attached source or from the ICD itself. Its signal is then detected by a sensor and correlated to the position and/or orientation of the transmitter. Examples of such systems are disclosed in U.S. Pat. Nos. 5,443,066; 6,995,729; 6,233,476; and U.S. Published Patent Application No. 2005/0099290, incorporated herein by reference.
In still another embodiment, the wireless sensor attached to the lead sends its sensed field measurements to the ICD device, which stores it for downloading to the clinician at a later time.
The device/lead combinations can be secured entirely within the heart wall or LV using corkscrew, helical anchor, harpoon, threaded member, hook, barb, fastener, suture, mesh or coating for receiving fibrous tissue growth.
Once at least one lead is placed, the sensor on the lead now functions to enable real time tracking of the absolute heart wall motion. The heart wall displacement is directly correlated to the maximum and minimum volume of heart chamber containing the sensor. This changing volume is useful for determining overall heart efficiency (assuming normal valve operation) and pumping capacity. When more then one lead with accompanying sensors are in place, the sensors on the leads now function to enable the “real time” tracking of multi-chamber heart wall motion. The relative motion of the multiple sensors will correspondingly be related to a direct measure of the mechanical efficiency of the heart (assuming normal valve operation). The displacements correspond to known hemodynamic indicators, such as volumetric measurement, and are shown to be strongly suggestive of hemodynamic performance. Tracking also provides information regarding how well synchronized the chambers are. This information could then be used to adjust the ICD to deliver better treatment. This could be done in a real-time mode, if the ICD has enough internal logic, or via the clinician.
When both an accelerometer and a tracking sensor are located on an implanted lead then the heart chambers' work function can be directly measured. Work occurs when a force is exerted over a displacement. Assuming a constant and determinable heart mass, the accelerometer measures the changing force (mass times acceleration) over time, where the tracking sensor will measure the absolute displacement over time. Thereby, the real-time work function (force times displacement) of the heart chamber is measured. This information could then be used to adjust the ICD to deliver better treatment. This could be done in a real-time mode, if the ICD has enough internal logic, or via the clinician. The work function may be utilized to control the ICD to optimize the heart muscle performance thereby optimizing or enhancing reverse heart remodeling. Of course, differentiating the sensor data one or more times can also provide velocity and acceleration information.
Another application that would not require tracking of leads occurs during an open-heart surgery. Wireless sensors can be attached to the heart walls during an open-heart procedure and can still be used for monitoring heart wall motion. This does not require any active pacing or defibrillating devices.
Another application is to provide a method for stabilizing heart motion when used with image fusion technologies. Knowing the motion of the heart enables the heart to be mathematically stabilized when overlaid on a fixed graphic image of the heart. This is valuable when used with pre-acquired images.
In certain embodiments, or when one is dealing with older pacemakers, a single lead is all that is necessary to provide heart motion wall feedback. The relative motion of the heart wall over time still provides valuable information to the clinician regarding the state and rate of heart failure.
The low cost magnetic generator/tracking can also be rapidly adapted for deploying into the home cardiac monitoring market. A home monitoring solution would provide continuous sleep time monitoring of “real time” cardiac mechanical performance. Further, the magnetic tracking field can be of sufficient field strength to provide power to the ICD/CRT implantable device. This is used to offset the power consumption required by the additional processing and communication requirements of the tracking system, and thereby maintaining and/or extending the device's battery life.
Transmission and reception means may be reversed as is known in the art. Depending on procedure and application, two different means may be required for tracking, e.g., an internal tracking method once the leads are placed, and an external tracking method for placing the leads. As such, an invention has been disclosed in terms of preferred embodiments thereof, which fulfill each and every one of the objects of the invention as disclosed, and provide new and useful lead tracking of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) devices of great novelty and utility.
Of course, various changes, modifications and alterations in the teachings of the present invention may be contemplated by those of ordinary skill in the art without departing from the intended spirit and scope thereof.
As such, it is intended that the present invention only be limited by the terms of the appended claims.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2007/005676 | 3/6/2007 | WO | 00 | 11/15/2007 |
Number | Date | Country | |
---|---|---|---|
60780073 | Mar 2006 | US |